Christopher Ogden - Jun 12, 2024 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Financial Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol
CTMX
Transactions as of
Jun 12, 2024
Transactions value $
$0
Form type
4
Date filed
6/14/2024, 04:24 PM
Previous filing
Mar 21, 2024
Next filing
Aug 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +17.5K +20.42% $0.00 103K Jun 12, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +75K $0.00 75K Jun 12, 2024 Common Stock 75K $1.49 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on June 12 of each year, with the first 1/3rd vesting on June 12, 2025, subject to the Reporting Person continuing as a service provider through each such date.
F2 Includes 77,810 RSUs.
F3 1/48th of the shares subject to the option vest on each monthly anniversary measured from June 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.